|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
The aim of this study was to compare the functional and morphological 1-year evolution of patients with exudative AMD treated with antivascular endothelial growth factor (VEGF) drugs with the CFH Y402H polymorphism in the Brazilian population.
|
28641277 |
2019 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
In our patients, p.I62V, but not p.Y402H, was significantly associated with an increased risk of AMD.
|
29367644 |
2018 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
Pooled overall odds ratios for RAP/AMD were 1.15 (95% CI 0.60-2.18) for GT versus GG, 3.52 (95% CI 1.25-9.91) for TT versus GG ARMS2, 0.98 (95% CI 0.22-4.29) for GA versus AA, 1.00 (95% CI 0.25-4.02) for GG versus AA CFHI62V, 0.57 (95% CI 0.35-0.93) for CT versus TT CFH Y402H, and 0.40 (95% CI 0.22-0.74) for CC versus TT CFH Y402H.
|
28005184 |
2017 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, higher levels of CRP in the presence of C allele of Y402H might confer more risk for the development of exudative AMD.
|
27778189 |
2017 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
AMD individuals who had at least one copy of the C allele of rs1061170 had an increased risk of disease compared with cases with the T allele.
|
25612476 |
2016 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
CFH Y402H SNP might be protective for AMD in the Turkish population.
|
27404493 |
2016 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
Younger age of exudative AMD onset was associated with the homozygous AA genotype of IL-8 rs4073 (p = 0.009, Mann-Whitney U-test), CC genotype of CFH rs1061170 (p = 0.016), TT genotype of ARMS2 rs10490924 (p = 0.001) and with current smoking (p = 0.002).
|
26154559 |
2015 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, pharmacogenetics of CFH Y402H polymorphism may play a role in response to anti-VEGF treatment for neovascular AMD, especially for Caucasians.
|
26411831 |
2015 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
After multivariate adjustment, CFH Y402H and ARMS2 A69S polymorphisms were associated with very high risk for exudative AMD (OR = 6.21 and OR = 11.7, respectively, p < 0.0001).
|
24362810 |
2014 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
The elevated systemic levels of selected proinflammatory cytokines, including those representing products of inflammasome activation, were associated with the CC at-risk variant of the Y402H polymorphism and suggest that genetic factors regulate the inflammatory status in dry AMD patients.
|
24083687 |
2013 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
There was a trend for association between the CFH Y402H T allele ("low risk" for AMD, n = 6) and improvement.
|
24113783 |
2013 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
Genotypes of 3 polymorphisms in known AMD susceptibility loci (rs1061170 in complement factor H (CFH), rs11200638 in HTRA1 and rs1413711 in VEGF) were determined.
|
24080590 |
2013 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
In the present study, exudative AMD is not associated to serum VEGF165 levels; furthermore, our data does not establish a statistical link between VEGF165 and the CFH Y402H polymorphism.
|
21158586 |
2011 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
The joint effects for complement factor H (CFH) Y402H and 10q26 variants indicated an increased risk of exudative AMD.
|
20456446 |
2010 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our data did not show significant association between the CFH Y402H polymorphism and PDT treatment response for neovascular AMD; however, CRP genetic variants were associated with a positive response to PDT treatment for neovascular AMD.
|
19692124 |
2009 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
Sixty-nine patients being treated for neovascular AMD with PDT were genotyped for the CFH Y402H and LOC387715 A69S polymorphisms by allele-specific digestion of PCR products.
|
18292785 |
2009 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
The G allele of the C3 IVS2 rs2250656, but not other tested C3 SNPs of rs2230205, rs10411506, rs2230199, rs339392, and rs163913, was significantly associated with a reduced risk for AMD in the Chinese population (OR 0.605, 95% CI 0.39-0.93, p = 0.023), even after adjusting for age, gender, smoking status, CFH rs1061170, CFB rs4151667, and CFB rs641153 allele status (OR 0.58, 95% CI 0.35-0.96, p = 0.033).
|
19899988 |
2009 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
There was no significant difference in the incidence of CFH Y402H (P = 0.598) and HTRA1 rs11200638 (P = 0.290) between eyes with typical exudative AMD and with PCV.
|
18939352 |
2008 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
Y402H polymorphism which has been suggested to be a major risk factor of AMD in Caucasians was found to be only marginally associated with exudative AMD with low frequency, whereas three adjacent SNPs in the CFH gene were significantly associated with AMD in Koreans.
|
18223247 |
2008 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
After controlling for environmental risk factors, CFH and HTRA1 SNPs were independently associated with exudative AMD, with OR of 3.50 (1.45 - 8.45) for CT genotype in Y402H, 3.34 (1.33 - 8.36) for GG genotype in rs1410996 and 3.85 (1.58 - 9.42) for AA genotype in rs11200638 respectively.
|
19187590 |
2008 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
Genotyping for the Tyr402His variant was performed in 240 NVAMD patients (78.1+/-7 age range) and 118 controls (70.8+/-8.2 age range).
|
18852870 |
2008 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
The AMD-associated CFH Y402H and LOC387715 A69S variants were associated with differences in choroidal neovascular lesion size in this study.
|
18054635 |
2007 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
Binary logistic regression analysis binary logistic regression analysis revealed an odds ratio (OR) of 2.7 (95% confidence interval (CI): 1.1-6.8) for AMD among subjects heterozygous for the HTRA1 -625A allele compared to those with the wildtype genotype, when adjusted for CFH Y402H genotypes (p=0.034).
|
17679948 |
2007 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our data suggest that the CFH Y402H polymorphism is a major risk factor for exudative AMD in a Central European population.
|
17398321 |
2007 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
Ethnic variation in AMD-associated complement factor H polymorphism p.Tyr402His.
|
16865697 |
2006 |